How Lurbinectedin Targets Cancer Cells
Lurbinectedin (Zepzelca) is an alkylating agent that binds to DNA minor grooves, forming covalent adducts that block transcription and cause double-strand DNA breaks. This traps PARP1 and other proteins on DNA, triggering cell cycle arrest and apoptosis, primarily in rapidly dividing tumor cells.[1][2]
It selectively kills cancer cells with high transcription rates and DNA repair deficiencies, sparing normal cells with lower activity.[1]
Primary Approval: Small Cell Lung Cancer
FDA approved in 2020 for metastatic small cell lung cancer (SCLC) after platinum-based chemotherapy. Administered intravenously at 3.2 mg/m² every 21 days, it extends median survival by about 2 months versus standard care (11.2 vs. 9.7 months in trials).[1][3]
Use in Other Cancers
- Mesothelioma: Granted orphan drug status; phase II trials show 21% response rate in pleural mesothelioma post-platinum/pemetrexed.1
- Sarcomas: Active in soft tissue sarcomas like L-sarcomas; phase II data report 25-30% response rates.[1]
- Breast and Ovarian Cancers: Early trials indicate activity in triple-negative breast cancer (response ~20%) and platinum-resistant ovarian cancer.[1][2]
- Other Solid Tumors: Explored in head/neck, biliary tract, and neuroendocrine cancers via basket trials, with responses in 10-25% of heavily pretreated patients.[1]
Off-label or investigational use expands to homologous recombination repair-deficient tumors.[2]
How It Differs from Chemotherapy
Unlike broad alkylators like cyclophosphamide, lurbinectedin traps transcription factors, exploiting tumor-specific vulnerabilities like high MYC expression in SCLC. It pairs with immunotherapy (e.g., doxorubicin) to boost efficacy without excessive myelosuppression.[1][3]
Common Side Effects Patients Experience
Myelosuppression (neutropenia in 50-70%), fatigue, nausea, and elevated liver enzymes. Infusion reactions occur in <5%; premedication with dexamethasone helps.[1][3]
Ongoing Trials and Future Approvals
Over 50 trials test combinations: with irinotecan for SCLC (IMforte trial), atezolizumab for extensive-stage SCLC, and doxorubicin for sarcomas. Pediatric studies underway for Ewing sarcoma.1
Sources
[1]: DrugPatentWatch.com - Lurbinectedin
[2]: FDA Label - Zepzelca
[3]: Trigo et al., Lancet Oncol 2020 (IMpower133 extension)